Clinic Roundup
NewLink Genetics Corp., of Ames, Iowa, has passed the midpoint in enrollment in its Phase III hyperacute pancreas immunotherapy product candidate (algenpantucel-L) trial with full enrollment projected to be completed by the end of 2013.
To continue reading subscribe now to BioWorld Today
Learn More about BioWorld Today
Already a subscriber? Sign In or Buy now to activate your subscription
Note: our contact information has changed
Customer Care: http://support.clarivate.com
© 2018 Clarivate Analytics.
Reproduction, reposting content is strictly prohibited.
Reproduction, reposting content is strictly prohibited.